Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05740839
Other study ID # 22-505
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 4, 2023
Est. completion date May 31, 2025

Study information

Verified date February 2024
Source Dana-Farber Cancer Institute
Contact Christina Dieli-Conwright, PhD, MPH
Phone 617-582-8321
Email ChristinaM_Dieli-Conwright@dfci.harvard.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether a 16-week virtual, home-based, high-intensity interval training (HIIT) exercise program will improve physical, cognitive, and emotional health among young adult survivors of pediatric brain tumors. The names of the study interventions involved in this study are/is: - High-Intensity Interval Training (HIIT)


Description:

This is a Pilot/Feasibility, randomized control, research study that will compare an exercise group to a control group on physical, social, and overall quality of life needs of pediatric brain tumor survivors who are now young adults. Participants will be randomized (selected at random) for two groups: HIIT program group will complete a 16-week intervention period followed by a 16-week period with no intervention and the waitlisted control group will complete a 16-week period and will perform their usual, daily activities followed by an optional 16-week period in which they can complete the HIIT program. Research procedures include screening for eligibility, study treatment including in-clinic evaluations of fitness and strength, blood collection, at-home zoom exercise sessions, self-administered activity logs, and survey questionnaires. Participation in this research study is expected to last about 8 months. It is expected that about 30 people will take part in this research study. The Stahl Family Charitable Foundation, Pedal 4 Pediatrics, and the Childhood Brain Tumor Foundation are supporting this research study by providing funding for the study.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date May 31, 2025
Est. primary completion date January 31, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 39 Years
Eligibility Inclusion Criteria: - Written informed consent prior to any study-related procedures. - At time of study are a young adult, aged 18-39 years. - Histologically diagnosed brain tumor during childhood (diagnosed =18 years). - Are at least 2 years post tumor-directed therapy. - The effects of exercise on the developing fetus are unknown. For this reason, women of child-bearing potential must agree to undergo a pregnancy test and to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation. Should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately. - Medically cleared to participate in exercise by their referred physician or a certified clinical exercise physiologist. - Are without medical conditions that could exacerbate with exercise, such as bone disease (excluding bone metastases) at imminent risk of fracture or uncontrolled cardiopulmonary or metabolic diseases. - Speak English and/or Spanish. - Currently participate in less than or equal to 60 minutes of moderate or vigorous structured exercise/week. - Does not smoke or vape (no smoking/vaping during previous 12 months). - Willing to travel to DFCI for necessary data collection. - Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: - Diagnosis of primary spinal cord tumor. - Pre-existing medical conditions such as uncontrolled cardiopulmonary disease, or metabolic diseases that could exacerbate with exercise. - Patients with active malignancies. - Patients who are pregnant. - Actively on a weight loss diet. - Participate in more than 60 minutes of moderate or vigorous structured exercise/week. - Currently smokes or vapes. - Unable to travel to DFCI for necessary data collection. - May not be able to comply with the safety monitoring requirements of the study in the opinion of the investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
HIIT Exercise Program
Exercise program with stationary bike via the Zoom platform.
Control Group
Usual Activities

Locations

Country Name City State
United States Dana Farber Cancer Institute Boston Massachusetts

Sponsors (4)

Lead Sponsor Collaborator
Dana-Farber Cancer Institute Pedals For Pediatrics, Stahl Family Charitable Foundation, The Childhood Brain Tumor Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Attendance of Exercise Sessions Defined as participant attendance of >= 70% of the 48 HIIT exercise sessions. From first exercise session to final exercise session, up to 16 weeks
Primary Completion in Minutes of Exercise Sessions Defined as participant completion of >= 70% of the 90 minutes of exercise per week From first exercise session to final exercise session, up to 16 weeks
Primary HIIT Compliance Defined as obtaining +-5W of target power output for >= 40 seconds of high intensity minute From first exercise session to final exercise session, up to 16 weeks
Primary Barriers to Exercise Adherence Assessed through the 17-item Barriers to Recruitment Participation Questionnaire (BRPQ), 1-5 scale with 1 denoted as strongly agree and 5 as strongly disagree. From first exercise session to final exercise session, up to 16 weeks
Primary Participant Burden Assessed through the Perceived Research Burden Assessment (PRBA), 1-5 scale with 1 denoted as strongly disagree and 5 as strongly agree. From first exercise session to final exercise session, up to 16 weeks
Secondary Cognition An assortment of tests will be executed through the NIH toolbox to measure overall cognition. : From baseline to post-intervention, up to 43 weeks
Secondary Cardiorespiratory Fitness Assessed through the use of a VO2 max (or submaximal if equipment is unavailable) cycle exercise stress test (Parvo Medics TrueOne 2400; Sandy, UT, USA). From baseline to post-intervention, up to 43 weeks
Secondary Muscular Strength 10-repetition maximum will be used to assess muscular strength. From baseline to post-intervention, up to 43 weeks
Secondary Body Composition Bioelectrical Impedance Analysis (BIA), and blood pressure as measured twice on both arms with a seated position with a minimum of 1-minute interval and the higher pressure will be recorded when there are differences.
BIA: Assessed via bioelectrical impedance using a validated device (Tanita 780, Arlington Heights, IL). Participants will be asked to remove their shoes and socks after which height will be taken using a stadiometer they will then proceed to move to the BIA and stand still on the device while holding the handles with their hands at their sides. The device will estimate body fat using an algorithm based on their age, sex, height, and body weight.
From baseline to post-intervention, up to 43 weeks
Secondary Fatigue BFI: A questionnaire of scale ratings 0 - 10 that focuses on cancer-related fatigue and tiredness. From baseline to post-intervention, up to 43 weeks
Secondary Psychosocial Health Assessed through the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire, which is comprised of 27 items with scale ratings validated to measure physical, emotional, social, and functional well-being of cancer patients and survivors From baseline to post-intervention, up to 43 weeks
Secondary Quality of Sleep Assessed through the Pittsburg Sleep Quality Index (PSQI), which is used to measure 7 components of the quality and patterns of sleep in participants. From baseline to post-intervention, up to 43 weeks
Secondary Dietary Assessment, ASA-24 Participants will be provided with a login to enter dietary data measured by an automated, online self-administered 24-hour assessment tool. Up to 3 days
Secondary ActiGraph - Physical Activity Monitoring Participants will be provided with an accelerometer (ActiGraph, Pensacola, FL) to wear for seven days at baseline and post-intervention testing visits and will be instructed to wear the water-resistant accelerometer at all times except for when swimming or bathing. The device will record activity data and will be electronically transferred to a computer via USB cable at time of completion. From baseline to post-intervention, up to 27 weeks
Secondary Exercise Tolerance Will be recorded using the Exercise-Induced Feeling Inventory (EIF). Based on a 0-4 scale, it assesses the participant's feeling state change(s) post-exercise and is also used for the assessment of self-motivation to adhere to an exercise regimen. Participants will be asked to complete the inventory before and after each exercise session. From baseline to week 16, up to 32 weeks
Secondary Pain Index BPI: A 9 item questionnaire to evaluate the severity of pain and the impact of pain on the participant's daily functioning. From baseline to post-intervention, up to 43 weeks
Secondary Hip and Waist Circumference Hip and waist circumference will be assessed and recorded in cm. From baseline to post-intervention, up to 43 weeks
See also
  Status Clinical Trial Phase
Withdrawn NCT03068832 - Neoepitope-based Personalized Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors Phase 1
Terminated NCT03330197 - A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG Phase 1/Phase 2
Active, not recruiting NCT03911388 - HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors Phase 1
Recruiting NCT05367076 - Fitness to Aid the Brain and Cognitive Skills N/A
Completed NCT03615404 - Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma Phase 1
Completed NCT04351035 - National Wide Cross-sectional Study in Paediatric Central Nervous System Tumours in China -- the CNOG-MC001 Registry
Completed NCT01707836 - Neurofibromatosis Type 1 Brain Tumor Genetic Risk N/A
Withdrawn NCT03577600 - Compassionate Treatment in Children With Brain Tumors With the Cytotron® N/A
Completed NCT04659421 - Study of Recombinant Human Endostatin Combined With CV Regimen in the Treatment of Pediatric Low-grade Gliomas Phase 2
Active, not recruiting NCT03739372 - Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma N/A
Recruiting NCT05887882 - Intra-Tumoral Injections of Natural Killer Cells for Recurrent Malignant Pediatric Brain Tumors Phase 1
Suspended NCT03334162 - Playful Sensorimotor Training in Pediatric Brain Tumor Patients N/A
Withdrawn NCT01861990 - Valproic Acid in Childhood Progressive Brain Tumors Phase 1
Recruiting NCT06226519 - Integrated PET/MRI and Germline Variants to Differentiate Brain Tumopr Recurrence From Iatrogenicchanges in Children
Terminated NCT03591861 - Therapeutic Targeting of Sex Differences in Pediatric Brain Tumor Glycolysis N/A
Completed NCT04944875 - Effects of Music and Maternal Voice on Sedation Depth and Sedative Use During Pediatric Magnetic Resonance Imaging. N/A
Completed NCT03434262 - SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors Phase 1
Recruiting NCT04239092 - 9-ING-41 in Pediatric Patients With Refractory Malignancies. Phase 1
Active, not recruiting NCT03208387 - Understanding the Late Effects of Surviving a Pediatric Brain Tumor
Recruiting NCT05528939 - Feasibility/Acceptability of Attentional-Control Training in Survivors N/A